Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.
Company Growth (employees)
Type
Public
HQ
Woodcliff Lake, US
Size (employees)
67 (est)
Eagle Pharmaceuticals is headquartered in Woodcliff Lake, US

Key People at Eagle Pharmaceuticals

Scott L. Tarriff

Scott L. Tarriff

President

Eagle Pharmaceuticals Office Locations

Eagle Pharmaceuticals has offices in Woodcliff Lake, Orlando, San Francisco, Chicago and in 15 other locations
Woodcliff Lake, US (HQ)
470 Chestnut Ridge Road

Eagle Pharmaceuticals Data and Metrics

Eagle Pharmaceuticals Financial Metrics

Eagle Pharmaceuticals's revenue was reported to be $189.5 m in FY, 2016 which is a 186% increase from the previous period.
USD

Revenue (FY, 2016)

189.5 m

Revenue growth (FY, 2015 - FY, 2016), %

186%

Net income (FY, 2016)

8.1 m

EBIT (FY, 2016)

53.4 m

Market capitalization (26-Jun-2017)

1.3 b

Closing share price (26-Jun-2017)

81.7

Cash (31-Dec-2016)

52.8 m
Eagle Pharmaceuticals's current market capitalization is $1.3 b.
USDFY, 2014FY, 2015FY, 2016

Revenue

19.1 m66.2 m189.5 m

Revenue growth, %

247%186%

R&D expense

16.8 m27.9 m30.3 m

Operating expense total

37.9 m63.7 m136.1 m

EBIT

(18.8 m)2.6 m53.4 m

EBIT margin, %

(98%)4%28%

Pre tax profit

19.3 m2.6 m53.4 m

Net Income

18 m2.6 m8.1 m
USDFY, 2014FY, 2015FY, 2016

Cash

34.9 m79.1 m52.8 m

Accounts Receivable

12 m26.3 m42.2 m

Inventories

1.2 m15 m11.4 m

Current Assets

49.7 m122.3 m109.1 m

PP&E

342 k2.2 m3.3 m

Total Assets

50.1 m124.6 m214.3 m

Accounts Payable

3.5 m3.9 m14.7 m

Current Liabilities

22.2 m34.3 m41 m

Additional Paid-in Capital

137.6 m197.4 m213.9 m

Retained Earnings

(109.7 m)(107.1 m)(25.7 m)

Total Equity

27.9 m90.3 m151.2 m

Financial Leverage

1.8 x1.4 x1.4 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(18 m)2.6 m81.5 m

Accounts Receivable

(2.2 m)(14.3 m)(15.9 m)

Inventories

(1.3 m)(13.8 m)12.3 m

Accounts Payable

2.9 m356 k10.7 m

Cash From Operating Activities

(13.8 m)(9.7 m)53.2 m

Purchases of PP&E

(46 k)(1.9 m)(1.6 m)

Cash From Investing Activities

(20 m)(1.9 m)(45.8 m)

Cash From Financing Activities

46.2 m55.8 m(33.7 m)
USDY, 2016

Revenue/Employee

4.6 m

Financial Leverage

1.4 x

Eagle Pharmaceuticals Market Value History

Eagle Pharmaceuticals Online and Social Media Presence

Eagle Pharmaceuticals Company Life and Culture

You may also be interested in